Special Issue

Technologies and Applications of Genome Editing

Message from the Guest Editor

Genome editing has revolutionized modern biology by enabling precise and efficient modification of genetic sequences. CRISPR/Cas systems in particular have become indispensable tools for creating animal models that replicate human disease phenotypes, providing critical platforms for studying disease mechanisms and developing novel therapeutic strategies. In this Special Issue, "Technologies and Applications of Genome Editing", we aim to highlight cutting-edge advances in genome editing strategies, delivery systems, and functional applications across diverse fields. Topics include novel editing approaches, improvements in accuracy and efficiency, and innovative uses in generating preclinical models. We welcome contributions that showcase technical innovations. successful case studies, and future directions that demonstrate how genome editing can accelerate translational research and drive breakthroughs in health and biotechnology.

Guest Editor

Dr. Fu-Lei Tang

Transgenic & Genome Editing Core, Medical University of South Carolina, Charleston, SC 29425, USA

Deadline for manuscript submissions

30 June 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/261966

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).